GLP-1 Drugs and Thyroid Cancer: Review Finds No Conclusive Evidence of Risk in Humans | Research

The takeaway

Despite a black box warning from rodent studies, there is no conclusive evidence that GLP-1 receptor agonists increase thyroid cancer risk in humans.

No conclusive evidence of increased risk
Across randomized trials, observational studies, and pharmacovigilance data, there is no consistent evidence that GLP-1 receptor agonists increase thyroid cancer risk in humans.

What the researchers found

Despite a black box warning based on rodent studies showing a link between GLP-1 receptor agonists and medullary thyroid cancer (MTC), this narrative review finds no conclusive evidence of elevated thyroid cancer risk in humans. Randomized controlled trials show thyroid cancer is rare in GLP-1 RA users, with imprecise effect estimates that do not consistently demonstrate increased risk. Observational studies yield inconsistent results. While pharmacovigilance databases show increased thyroid cancer reporting, these studies cannot establish causation. The biological plausibility for MTC in rodents does not clearly extend to non-MTC thyroid cancer in humans.

Why it matters

The thyroid cancer black box warning on GLP-1 receptor agonists like semaglutide and liraglutide has caused significant patient anxiety and may be leading to underuse of these highly effective medications. This review helps clinicians and patients put the risk in perspective: while the warning is based on real rodent data, human evidence does not support a clear thyroid cancer link. Unwarranted fear could also lead to unnecessary thyroid screening and overdiagnosis.

The numbers in context

Review of RCTs, observational studies, and pharmacovigilance data · thyroid cancer is rare across all study types · effect estimates imprecise · no consistent evidence of increased risk

How the study worked

This is a narrative review that synthesizes evidence across four categories: basic/translational research on biological plausibility, randomized controlled trials, observational studies with real-world outcomes, and pharmacovigilance (postmarketing safety) databases. Each evidence type is evaluated for its strengths and limitations in addressing the GLP-1 RA–thyroid cancer question.

Who was studied

Review of evidence across patients with type 2 diabetes and obesity treated with GLP-1 receptor agonists

What this study cannot tell us

As a narrative review, the evidence synthesis is qualitative rather than quantitative. The low frequency of thyroid cancer events in clinical trials makes it difficult to definitively rule out small risk increases. Observational studies have inherent biases including inconsistent outcome definitions. Pharmacovigilance data reflect reporting patterns rather than true incidence rates.

How to read the evidence

This is a narrative review synthesizing evidence from multiple study types including RCTs, observational studies, and pharmacovigilance data. While not a systematic review or meta-analysis, it provides a comprehensive qualitative assessment of the available evidence across the hierarchy of study designs.

When this study was published

Published in 2024, this review is current and reflects the latest evidence including data from cardiovascular outcome trials and expanded real-world use of GLP-1 receptor agonists.

The bigger picture

With millions of people now taking GLP-1 receptor agonists for diabetes and obesity, the thyroid cancer question is one of the most important safety concerns in peptide therapeutics. This review contributes to a growing consensus that the rodent-based warning may not translate to meaningful human risk, though it appropriately calls for continued monitoring. As these drugs become more widely used, long-term registry data will ultimately provide the definitive answer.

Questions still open

Will long-term population-level data from the massive expansion of GLP-1 RA use finally settle the thyroid cancer question?
Should the black box warning for MTC be revised or removed based on the accumulated human evidence?
Does duration of GLP-1 RA exposure matter — could very long-term use (10+ years) reveal a risk not detectable in shorter studies?

Common questions

Why do GLP-1 drugs have a thyroid cancer warning if there's no proven risk in humans?

The black box warning is based on studies in rodents (rats and mice) where GLP-1 receptor agonists caused thyroid C-cell tumors, including medullary thyroid cancer. However, rodent thyroid C-cells have many more GLP-1 receptors than human C-cells, and the biological mechanism that causes these tumors in rodents may not apply to humans. Regulatory agencies added the warning as a precaution, but human evidence has not confirmed the risk.

Should I get my thyroid checked more often if I'm taking a GLP-1 drug?

Based on current evidence, there is no recommendation for additional thyroid cancer screening in GLP-1 RA users beyond standard clinical care. The review authors actually caution that unnecessary screening could lead to overdiagnosis — finding small thyroid nodules that would never cause harm but lead to anxiety and potentially unnecessary procedures. Discuss any concerns with your doctor.

Read the original research

Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer: A Narrative Review.

Thyroid : official journal of the American Thyroid Association, 34(4), 403-418

View on PubMed ↗Publisher’s paper ↗

Citation

Espinosa De Ycaza, Ana E; Brito, Juan P; McCoy, Rozalina G; Shao, Hui; Singh Ospina, Naykky. (2024). Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer: A Narrative Review.. Thyroid : official journal of the American Thyroid Association, 34(4), 403-418. https://doi.org/10.1089/thy.2023.0530